RxDoctor Payments Data

William Martin, MD

Internal Medicine · Sarasota, FLNPI 1952397184

Payments from drug & device makers

$827in general payments, 2019–2025

Across 33 payments — averaging $25.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$154
  • Centinel Spine, LLC$133
  • Exact Sciences$121
  • Pfizer$84
  • Lilly USA, LLC$47
  • GSK$39
  • plus $250 from 10 others

What the payments were for

  • Food & beverage$827100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$827 in reported general payments places this provider in the 65th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$428,677
Medicare patients
1,030
Services billed
9,294

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide175$187,457
JardianceEmpagliflozin80$118,084
EliquisApixaban86$109,521
Sandostatin Lar DepotOctreotide Acetate,mi-Spheres13$89,235
XareltoRivaroxaban44$58,461
JanuviaSitagliptin Phosphate36$53,848
Trelegy ElliptaFluticasone/Umeclidin/Vilanter58$41,641
MyrbetriqMirabegron44$35,803
FarxigaDapagliflozin Propanediol23$29,925
MounjaroTirzepatide23$25,328
TrulicityDulaglutide16$16,016
WegovySemaglutide12$15,365
Rosuvastatin Calcium864$11,624
Atorvastatin Calcium839$7,028
SynthroidLevothyroxine Sodium113$6,992

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Wegovy$154$202,822187 claims
Boehringer IngelheimJardiance$30$118,08480 claims
PfizerEliquis, Paxlovid$84$112,379134 claims
MerckJanuvia$28$53,84836 claims
GSKTrelegy Ellipta$39$41,64158 claims
Lilly USA, LLCMounjaro, Trulicity$47$41,34539 claims
AstraZenecaFarxiga, Symbicort$32$34,40436 claims
AbbVieSynthroid$14$6,992113 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Sarasota

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →